Changes in Hong Kong stocks | Verishibo-B (09887) has risen more than 11% in the past 3 days, and its stock price has risen by more than 30%, and many research results were selected for 2026 ESMO

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Weilizhibo-B (09887) has risen by more than 11%, and its stock price has risen by more than 30% in the past three trading days. As of press release, it rose 11.45% to HK$67.15, with a turnover of HK$166 million.

According to the news, Weilizhibo recently announced the 2026 ESMO selection results. Six of the latest research results have been confirmed, including two high-standard oral reports. It is expected that the LBA will also be selected in September. Earlier, the company also announced that LBL-024 was selected by 1L NSCLC to hold an oral report at the World Lung Cancer Conference (WCLC) in September this year.

It is worth mentioning that Weilizhibo also recently revealed that its core pipeline LBL-024 listing application was eligible for priority review. The company said that this milestone marks the official closure of the commercialization schedule for Velisign®, and it is clear that the time for approval to go public can be expected. At the same time, the company is actively promoting various commercialization preparations before listing.